You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

CLINICAL TRIALS PROFILE FOR HIBICLENS


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for HIBICLENS

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT04021524 ↗ BPO vs Hibiclens Soap for Surgical Preparation Unknown status University of Washington Phase 4 2018-09-10 This is a randomized trial of benzoyl peroxide soap versus Hibiclens soap for surgical preparation. The objective is to determine whether benzoyl peroxide soap, commonly available in drug stores for over-the-counter acne treatment, is as or more effective than the standard surgical preoperative soap, Hibiclens soap (chlorhexidine gluconate), in reducing loads of Propionibacteria (Propi) on or under the skin of patients prior to shoulder arthroplasty (joint replacement).
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for HIBICLENS

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00513799 ↗ The Natural History of Community-Associated MRSA Infections and Decolonization Strategies Completed Washington University School of Medicine N/A 2007-03-01 The purpose of this study is to determine the natural history of community-associated Staphylococcus aureus infections in both adult and pediatric patients by monitoring the rate of recurrent infections in those colonized with S. aureus. In addition, this study will evaluate the efficiency of commonly prescribed decolonization measures in patients presenting with S. aureus skin and soft tissue infections.
NCT00731783 ↗ Staphylococcus Aureus Decolonization Study Completed Washington University School of Medicine N/A 2008-07-01 The purpose of this study is to determine whether measures to eliminate the Staph germ from the skin of the index patient (with a special ointment and soap) are more effective when performed by everyone in the household rather than the patient alone, and whether these methods are effective in preventing future Staph infections. The investigators hypothesize that there will be a greater number of households who are successful in eradicating the staph germ from the index patient when all members of the household participate than households where only the index patient is treated.
NCT00799812 ↗ Test for Pre Operative Skin Preparations Completed CareFusion Phase 3 2007-11-13 Compare 2 application techniques of ChloraPrep Swabstick--3 swabsticks at once versus 3 swabsticks used sequentially. Hibiclens applied according to the manufacturer's directions. Sterile swabsticks (wetted with sterile deionizd water) applied using the same method as the ChloraPrep Swabstick.
NCT01196169 ↗ Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty Terminated Cubist Pharmaceuticals LLC Phase 4 2010-10-01 This study will evaluate the safety and effectiveness of daptomycin, an antibiotic compared to another one which is vancomycin when given around the time of joint replacement surgery. Vancomycin is recommended for perioperative prophylaxis in methicillin resistant Staphylococcus aureus (MRSA) colonized patients undergoing primary total joint arthroplasty. Daptomycin has not been recommended for this indication but it is FDA approved for treatment of MRSA blood stream and skin and soft tissue infections. Data collected during this study may support the use of daptomycin for this indication and may also be used for other research purposes that have not yet been specified.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for HIBICLENS

Condition Name

Condition Name for HIBICLENS
Intervention Trials
Staphylococcal Skin Infections 3
Staphylococcus Aureus 3
Furunculosis 2
Methicillin-resistant Staphylococcus Aureus 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for HIBICLENS
Intervention Trials
Infections 6
Infection 5
Staphylococcal Infections 5
Communicable Diseases 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for HIBICLENS

Trials by Country

Trials by Country for HIBICLENS
Location Trials
United States 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for HIBICLENS
Location Trials
Missouri 4
Maryland 2
Tennessee 2
Virginia 2
Washington 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for HIBICLENS

Clinical Trial Phase

Clinical Trial Phase for HIBICLENS
Clinical Trial Phase Trials
Phase 4 8
Phase 3 1
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for HIBICLENS
Clinical Trial Phase Trials
Completed 8
Recruiting 3
Unknown status 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for HIBICLENS

Sponsor Name

Sponsor Name for HIBICLENS
Sponsor Trials
Washington University School of Medicine 3
Johns Hopkins University 2
Cubist Pharmaceuticals LLC 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for HIBICLENS
Sponsor Trials
Other 21
Industry 2
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.